← Back to Clinical Trials
Recruiting NCT07485322

NCT07485322 Burn Pit Exposure in Veterans: A Cancer Screening Pilot Study at the Inova Saville Cancer Screening & Prevention Center

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07485322
Status Recruiting
Phase
Sponsor Inova Health Care Services
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2026-06-17
Primary Completion 2029-04-28

Eligibility & Interventions

Sex All sexes
Min Age 35 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Avantect Multi-Cancer Detection TestNasal Swab

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2026-06-17 with a primary completion date of 2029-04-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to determine the feasibility and participant satisfaction associated with a more intensive cancer screening regimen in veterans exposed to burn pits. The study results may describe the clinical and psychosocial impact such screening has on this potential population. The study hopes to share the premalignant and malignant findings identified and follow-up healthcare utilization associated with high-intensity cancer screening during the approximately 3-year study period (three annual screening assessments and an additional year of follow-up to determine participants' cancer status). The study will also explore the performance of new tools (nasal brush, multi-cancer detection blood test, and radiomic analysis) in detecting the development of cancer during the study period.

Eligibility Criteria

Inclusion Criteria: * ≥ 35 years * Veteran of the United States Armed Forces (retired/no longer enlisted) with a prior deployment resulting in exposure (based on self-report or official records, if available) to burn pits for \>1 week (exposure defined as on the base or close enough to the base to see the smoke from the burn pit, an area of land used for the open-air combustion of trash and other solid waste products). * Ability to understand and willing to sign informed consent * Ability to understand and willing to sign HIPAA Authorization Exclusion Criteria: * No history of malignancy within the past 5 years (non-melanoma skin cancer and in situ carcinoma would still be eligible) and not currently being worked up clinically for suspicion of cancer. * For women of childbearing potential, not pregnant.

Contact & Investigator

Central Contact

Bryan Bassig, PhD

✉ bryan.bassig@inova.org

📞 (571) 472-3500

Principal Investigator

Rebecca Kaltman, MD

PRINCIPAL INVESTIGATOR

Inova Health Care Services

Frequently Asked Questions

Who can join the NCT07485322 clinical trial?

This trial is open to participants of all sexes, aged 35 Years or older, up to 85 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07485322 currently recruiting?

Yes, NCT07485322 is actively recruiting participants. Contact the research team at bryan.bassig@inova.org for enrollment information.

Where is the NCT07485322 trial being conducted?

This trial is being conducted at Fairfax, United States.

Who is sponsoring the NCT07485322 clinical trial?

NCT07485322 is sponsored by Inova Health Care Services. The principal investigator is Rebecca Kaltman, MD at Inova Health Care Services. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology